Cancer Monoclonal Antibodies Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2017 to 2021 and Forecast 2022 to 2028

$ PRICE - $ 3,000.00$ 8,900.00

Cancer Monoclonal Antibodies Market: By Application (Breast Cancer, Blood Cancer, Liver Cancer, Brain cancer, Colorectal Cancer, Other) By type of antibody (Murine Antibodies, Humanized Antibodies, Chimeric Antibodies), Based on conjugation (Immunocytokines, Immunoliposome, Radioimmunotherapy, Antibody Directed Enzyme Prodrug Therapy(ADEPT)), By distribution channel (Hospital Pharmacies, Retail Pharmacie, Online Pharmacies) – Geography

 

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Categories: ,

Report

Description

Cancer Monoclonal Antibodies Market size was valued at USD 47.2 billion and expected to grow at CAGR of 11.8% during 2022-2028. A monoclonal antibody drug in cancer treatments engages natural immune system functions to fight cancer. Cancer monoclonal antibodies may be used in combination with other cancer treatments. An antibody attaches itself to a specific molecule (antigen) on the surface of cancer cell when antibody binds to antigen, it acts as a flag to attract disease-fighting molecules or as a trigger that promotes the destruction of cancer cells by another immune system process. Due to its specificity, monoclonal antibodies have least adverse effects than other cancer treating drugs. Currently cancer monoclonal antibodies market is witnessing a significant growth. The targeted and combination therapy drugs are leading in the market. Several market player collaborating to develop antibody drugs to treat various type of cancers. In January 2017, AbCellera Biologics, Inc. collaborated with Pfizer Inc. for new therapeutic antibody discovery. AbCellera will use its monoclonal antibody (mAb) screening techniques in the discovery of function modulating antibodies against undisclosed membrane protein targets. Academic institutions and organisations like National Institute of Health (USA), National Cancer Institute (USA) and many others are collaborating and participating in cancer research and awareness activities.

Key Developments:

In May 2017, the U.S. Food and Drug Administration (FDA) granted accelerated approval to AstraZeneca’s durvalumab (IMFINZI) for the treatment of patients with locally advanced or metastatic urothelial carcinoma

In 2016, U.S Food and Drug Administration (FDA) approved Genentech Oncology’s tecentriq (atezolizumab) for the treatment of patients with metastatic non-small cell lung cancer

 

Cancer Monoclonal Antibodies Market

MARKET SUMMARY
-
11.8% CAGR
  • Study Period– 2022 – 2028
  • Base Year– 2021
  • CAGR– 11.8%
  • Largest Market– North America
  • Fastest Growing Market– Asia-Pacific

Cancer Monoclonal Antibodies Market

  • The report on global Cancer Monoclonal Antibodies Market gives historical, current, and future market sizes (US$ Bn) on the basis on application, type and conjugation, distribution channel and geography.
  • Cancer Monoclonal Antibodies Market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
Key Players
  • Merck & Co. Inc. (U.S.)
  • Spectrum Pharmaceuticals (U.S.)
  • Eli Lilly and Company (U.S.)
  • Amgen Inc. (U.S.)
  • Sanofi  (France)
  • AstraZeneca (U.K.
Cancer Monoclonal Antibodies Market

Drivers And Restraints

The market growth of cancer monoclonal antibodies is driven by increased prevalence of cancer worldwide. According to WHO, cancer is one of the leading cause of deaths worldwide. In 2012, there were around 14 Mn new cases of cancer, 8.2 Mn people died because of cancer and numbers of new cancer cases are projected to rise 70% in coming decades. In addition, monoclonal antibodies are proved to be having less adverse effects when compared to conventional non-targeted therapies. Increasing investment in the development of monoclonal antibodies, technological advancements that enabling the genetic sequencing and increasing specificity of the antibodies are fueling the sales revenue ofcancer monoclonal antibodies market. However, the high cost of development, stringent regulatory guidelines, long period of clinical trials, are some of the factors hinder growth of cancer monoclonal antibodies market.


North-America Got Significant Share

Cancer Monoclonal Antibodies Market

Geographically cancer monoclonal antibodies market has been segmented into following regions viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America cancer monoclonal antibodies market is growing at a steady rate due to increased prevalence of various cancers and higher acceptance of existing monoclonal antibodies among healthcare professionals in the region. According to National Cancer Institute (NIH), an estimated 1,685,210 new cases of cancer were diagnosed in the United States and 595,690 people will die from the disease in 2016. Asia-Pacific region is expected to exhibit rapid growth due to rise in government spending on healthcare infrastructure, increasing R&D spending by companies and growing patient and healthcare professional awareness in therapeutic use of monoclonal antibodies in treatment of cancer. For instance, Government-led fund providers, such as National Natural Science Foundation and National Basic Research Program of China, offer financial support to enterprises and universities to conduct monoclonal antibody research and development. The presence of healthcare regulations and procedures to promote early treatment of diseases using advanced therapeutics and public policies to support early screening and effective treatments for various cancers is driving the cancer monoclonal antibodies market in Latin-America.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Features of the Report

  • The report provides granular level information about the market size, regional market share and forecast from 2022-2028
  • The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
  • The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
  • The report tracks recent innovations, key developments and startup’s details that are working in the industry
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
Segmentation

Cancer Monoclonal Antibodies Market


Location

GEOGRAPHY

Frequently Asked Questions

The cancer monoclonal antibodies market is projected to expand at a CAGR of 11.8% during the forecast period

Merck & Co. Inc. (U.S.), F. Hoffmann-La Roche AG (Switzerland), Spectrum Pharmaceuticals (U.S.), Eli Lilly and Company (U.S.), Amgen Inc. (U.S.), Bristol-Meyer Squibb (U.S.), Sanofi  (France)

North America is the fastest-growing region for cancer monoclonal antibodies market


Report

Table Of Content

  1. Executive summary
  2. Global Cancer Monoclonal Antibodies Market Introduction
    • Global Cancer Monoclonal Antibodies Market– Taxonomy
    • Global Cancer Monoclonal Antibodies Market–Definitions
      • Application
      • Distribution Channel
  1. Global Cancer Monoclonal Antibodies Market Dynamics
    • Drivers
    • Restraints
    • Opportunities/Unmet Needs of the Market
    • Trends
    • Global Cancer Monoclonal Antibodies Market Dynamics – Factors Impact Analysis
    • Global Cancer Monoclonal Antibodies Market– Regulations
      • US
      • Europe
      • Japan
    • Global Cancer Monoclonal Antibodies Market– Recent Product Launches
  2. Global Cancer Monoclonal Antibodies Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026
    • Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
    • Year-over-Year (Y-o-Y) Growth Analysis (%)
    • Market Oppurtunity Analysis
  3. Global Cancer Monoclonal Antibodies Market, By Application, 2015 – 2019 and Forecast, 2020 – 2026
    • Breast Cancer
      • Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Blood Cancer
      • Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Liver Cancer
      • Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Brain cancer
      • Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Colorectal Cancer
      • Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Others
      • Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Cancer Monoclonal Antibodies Market Forecast, By Type of Antibody, 2015 – 2019 and Forecast, 2020 – 2026
    • Murine Antibodies
      • Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Humanized Antibodies
      • Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Chimeric Antibodies
      • Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Cancer Monoclonal Antibodies Market Forecast, By Conjugation, 2015 – 2019 and Forecast, 2020 – 2026
    • Immunocytokines
      • Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Immunoliposome
      • Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Radioimmunotherapy
      • Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Antibody Directed Enzyme Prodrug Therapy(ADEPT)
      • Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Cancer Monoclonal Antibodies Market Forecast, By Distribution Channel, 2015 – 2019 and Forecast, 2020 – 2026
    • Hospital Pharmacies
      • Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Retail Pharmacies
      • Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Online Pharmacies
      • Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Cancer Monoclonal Antibodies Market Forecast, By Region, 2015 – 2019 and Forecast, 2020 – 2026
    • North America
      • Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Europe
      • Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Asia-Pacific
      • Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Latin America
      • Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Middle East and Africa
      • Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Global Cancer Monoclonal Antibodies Market- Opportunity Analysis Index – By Application, By Antibody Type, By Conjugation, By Distribution Channel, and Region, 2020 – 2026
  2. North America Cancer Monoclonal Antibodies Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026
    • Application Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Breast Cancer
      • Blood Cancer
      • Liver Cancer
      • Brain cancer
      • Colorectal Cancer
      • Others
    • Antibody Type Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Murine Antibodies
      • Humanized Antibodies
      • Chimeric Antibodies
    • Conjugation Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Immunocytokines
      • Immunoliposome
      • Radioimmunotherapy
      • Antibody Directed Enzyme Prodrug Therapy(ADEPT)
    • Distribution Channel Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Country Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • S.
      • Canada
    • North America Cancer Monoclonal Antibodies Market- Opportunity Analysis Index – By Application, By Antibody Type, By Conjugation, By Distribution Channel, and Country, 2020 – 2026
    • North America Cancer Monoclonal Antibodies Market Dynamics – Trends
  3. Europe Cancer Monoclonal Antibodies Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026
    • Application Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Breast Cancer
      • Blood Cancer
      • Liver Cancer
      • Brain cancer
      • Colorectal Cancer
      • Others
    • Antibody Type Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Murine Antibodies
      • Humanized Antibodies
      • Chimeric Antibodies
    • Conjugation Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Immunocytokines
      • Immunoliposome
      • Radioimmunotherapy
      • Antibody Directed Enzyme Prodrug Therapy(ADEPT)
    • Distribution Channel Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Country Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Germany
      • UK
      • France
      • Spain
      • Italy
      • Russia
      • Poland
      • Rest of Europe
    • Europe Cancer Monoclonal Antibodies Market- Opportunity Analysis Index – By Application, By Antibody Type, By Conjugation, By Distribution Channel, and Country, 2020 – 2026
    • Europe Cancer Monoclonal Antibodies Market Dynamics – Trends
  4. Asia-Pacific Cancer Monoclonal Antibodies Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026
    • Application Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Breast Cancer
      • Blood Cancer
      • Liver Cancer
      • Brain cancer
      • Colorectal Cancer
      • Others
    • Antibody Type Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Murine Antibodies
      • Humanized Antibodies
      • Chimeric Antibodies
    • Conjugation Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Immunocytokines
      • Immunoliposome
      • Radioimmunotherapy
      • Antibody Directed Enzyme Prodrug Therapy(ADEPT)
    • Distribution Channel Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Country Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn),
  5. Y-o-Y Growth (%), and Market Share (%)
    • Japan
    • China
    • India
    • ASEAN
    • Australia & New Zealand
    • Rest of Asia-Pacific
  • Asia-Pacific Cancer Monoclonal Antibodies Market- Opportunity Analysis Index – By Application, By Antibody Type, By Conjugation, By Distribution Channel, and Country, 2020 – 2026
  • Asia-Pacific Cancer Monoclonal Antibodies Market Dynamics – Trends
  1. Latin America Cancer Monoclonal Antibodies Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026
    • Application Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Breast Cancer
      • Blood Cancer
      • Liver Cancer
      • Brain cancer
      • Colorectal Cancer
      • Others
    • Antibody Type Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Murine Antibodies
      • Humanized Antibodies
      • Chimeric Antibodies
    • Conjugation Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Immunocytokines
      • Immunoliposome
      • Radioimmunotherapy
      • Antibody Directed Enzyme Prodrug Therapy(ADEPT)
    • Distribution Channel Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Country Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Brazil
      • Mexico
      • Argentina
      • Venezuela
      • Rest of Latin America
    • Latin America Cancer Monoclonal Antibodies Market- Opportunity Analysis Index – By Application, By Antibody Type, By Conjugation, By Distribution Channel, and Country, 2020 – 2026
    • Latin America Cancer Monoclonal Antibodies Market Dynamics – Trends
  2. Middle East & Africa Cancer Monoclonal Antibodies Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026
    • Application Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Breast Cancer
      • Blood Cancer
      • Liver Cancer
      • Brain cancer
      • Colorectal Cancer
      • Others
    • Antibody Type Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Murine Antibodies
      • Humanized Antibodies
      • Chimeric Antibodies
    • Conjugation Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Immunocytokines
      • Immunoliposome
      • Radioimmunotherapy
      • Antibody Directed Enzyme Prodrug Therapy(ADEPT)
    • Distribution Channel Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Country Analysis (2015 – 2019) and Forecast (2020 – 2026) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Gulf Cooperation Council (GCC) Countries
      • Israel
      • South Africa
      • Rest of MEA
    • MEA Cancer Monoclonal Antibodies Market- Opportunity Analysis Index – By Application, By Antibody Type, By Conjugation, By Distribution Channel, and Country, 2020 – 2026
    • MEA Cancer Monoclonal Antibodies Market Dynamics – Trends
  3. Competition Landscape
    • Strategic Dashboard of Top Market Players
    • Company Profiles (Introduction, Financial Analysis, Drug & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
      • Merck & Co. Inc. (U.S.)
      • Hoffmann-La Roche AG (Switzerland)
      • Spectrum Pharmaceuticals (U.S.)
      • Eli Lilly and Company (U.S.)
      • Amgen Inc. (U.S.)
      • Bristol-Meyer Squibb (U.S.)
      • Sanofi (France)
      • AstraZeneca (U.K.)
  4. Research Methodology
  5. Key Assumptions and Acronyms

Report

Company Profile

  • Merck & Co. Inc. (U.S.)
  • F. Hoffmann-La Roche AG (Switzerland)
  • Spectrum Pharmaceuticals (U.S.)
  • Eli Lilly and Company (U.S.)
  • Amgen Inc. (U.S.)
  • Bristol-Meyer Squibb (U.S.)
  • Sanofi  (France)
  • AstraZeneca (U.K.)

Description

Cancer Monoclonal Antibodies Market size was valued at USD 47.2 billion and expected to grow at CAGR of 11.8% during 2022-2028. A monoclonal antibody drug in cancer treatments engages natural immune system functions to fight cancer. Cancer monoclonal antibodies may be used in combination with other cancer treatments. An antibody attaches itself to a specific molecule (antigen) on the surface of cancer cell when antibody binds to antigen, it acts as a flag to attract disease-fighting molecules or as a trigger that promotes the destruction of cancer cells by another immune system process. Due to its specificity, monoclonal antibodies have least adverse effects than other cancer treating drugs. Currently cancer monoclonal antibodies market is witnessing a significant growth. The targeted and combination therapy drugs are leading in the market. Several market player collaborating to develop antibody drugs to treat various type of cancers. In January 2017, AbCellera Biologics, Inc. collaborated with Pfizer Inc. for new therapeutic antibody discovery. AbCellera will use its monoclonal antibody (mAb) screening techniques in the discovery of function modulating antibodies against undisclosed membrane protein targets. Academic institutions and organisations like National Institute of Health (USA), National Cancer Institute (USA) and many others are collaborating and participating in cancer research and awareness activities.

Key Developments:

In May 2017, the U.S. Food and Drug Administration (FDA) granted accelerated approval to AstraZeneca’s durvalumab (IMFINZI) for the treatment of patients with locally advanced or metastatic urothelial carcinoma

In 2016, U.S Food and Drug Administration (FDA) approved Genentech Oncology’s tecentriq (atezolizumab) for the treatment of patients with metastatic non-small cell lung cancer

 

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX